Cargando…

Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment

Acute myeloid leukemia (AML) has high mortality rates, perhaps reflecting a lack of understanding of the molecular diversity in various subtypes and a lack of known actionable targets. There are currently 12 open clinical trials for AML using combination therapeutic modalities including all-trans re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bunaciu, Rodica P., MacDonald, Robert J., Gao, Feng, Johnson, Lynn M., Varner, Jeffrey D., Wang, Xin, Nataraj, Sarah, Guzman, Monica L., Yen, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790527/ https://www.ncbi.nlm.nih.gov/pubmed/29423110 http://dx.doi.org/10.18632/oncotarget.23642

Ejemplares similares

Retinoic Acid Therapy Resistance Progresses from Unilineage to Bilineage in HL-60 Leukemic Blasts
por: Jensen, Holly A., et al.
Publicado: (2014)

An Effective Model of the Retinoic Acid Induced HL-60 Differentiation Program
por: Tasseff, Ryan, et al.
Publicado: (2017)

6-Formylindolo (3,2-b)carbazole (FICZ) enhances retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells
por: Bunaciu, Rodica P, et al.
Publicado: (2013)

The Src-Family Kinase Inhibitor PP2 Rescues Inducible Differentiation Events in Emergent Retinoic Acid-Resistant Myeloblastic Leukemia Cells
por: Jensen, Holly A., et al.
Publicado: (2013)

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
por: Lambert, Juliette, et al.
Publicado: (2014)

Significance of NPM1 Gene Mutations in AML
por: Hindley, Andrew, et al.
Publicado: (2021)

The antagonistic duality of NPM1 mutations in AML
por: Khan, Irum, et al.
Publicado: (2022)

NPM 1 Mutations in AML—The Landscape in 2023
por: Sharma, Naman, et al.
Publicado: (2023)

RRD-251 enhances all-trans retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells
por: Wallace, Aaron S., et al.
Publicado: (2016)

Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML
por: Diaz de la Guardia, Rafael, et al.
Publicado: (2020)

6-Formylindolo(3,2-b)Carbazole (FICZ) Modulates the Signalsome Responsible for RA-Induced Differentiation of HL-60 Myeloblastic Leukemia Cells
por: Bunaciu, Rodica P., et al.
Publicado: (2015)

The AhR agonist VAF347 augments retinoic acid-induced differentiation in leukemia cells
por: Ibabao, Christopher N., et al.
Publicado: (2015)

Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML
por: Lopez, Amanda, et al.
Publicado: (2021)

Targeted therapy in NPM1-mutated AML: Knowns and unknowns
por: Wang, Rong, et al.
Publicado: (2022)

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
por: Fiskus, Warren, et al.
Publicado: (2022)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

CD123 Is Consistently Expressed on NPM1-Mutated AML Cells
por: Perriello, Vincenzo Maria, et al.
Publicado: (2021)

Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML
por: Duchmann, Matthieu, et al.
Publicado: (2022)

The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein
por: Pianigiani, Giulia, et al.
Publicado: (2022)

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1
por: Mill, Christopher P., et al.
Publicado: (2023)

A surrogate marker to detect nucleophosnim (NPM1) gene mutations in the cytoplasm of acute myeloid leukemia (AML) blast cells in 30 adult Iraqi patients
por: Al-Husseinawi, Ethar Kadhim
Publicado: (2013)

Epigenetic Priming of AML Blasts for All-trans Retinoic Acid-Induced Differentiation by the HDAC Class-I Selective Inhibitor Entinostat
por: Blagitko-Dorfs, Nadja, et al.
Publicado: (2013)

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Spontaneous remission in three cases of AML M5 with NPM1 mutation
por: Camus, Vincent, et al.
Publicado: (2015)

Biological and therapeutic implications of a unique subtype of NPM1 mutated AML
por: Mer, Arvind Singh, et al.
Publicado: (2021)

Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field
por: Falini, Brunangelo, et al.
Publicado: (2021)

NPM1 Mutational Status Underlines Different Biological Features in Pediatric AML
por: Tregnago, Claudia, et al.
Publicado: (2021)

Current status and future perspectives in targeted therapy of NPM1-mutated AML
por: Ranieri, Roberta, et al.
Publicado: (2022)

Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice
por: Muranyi, Andrew, et al.
Publicado: (2022)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

All‐trans retinoic acid (ATRA) in non‐promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low‐dose Ara‐C in three elderly patients with NPM1‐mutated AML unfit for intensive chemotherapy and review of the literature
por: Forghieri, Fabio, et al.
Publicado: (2016)

Induced myelomonocytic differentiation in leukemia cells is accompanied by noncanonical transcription factor expression
por: Jensen, Holly A., et al.
Publicado: (2015)

An intensive approach to treatment for older patients with relapsed isolated NPM1 mutated AML
por: Dukka, Srivasavi, et al.
Publicado: (2015)

Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
por: Cappelli, Luca Vincenzo, et al.
Publicado: (2021)

The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation
por: Meier, Ruth, et al.
Publicado: (2022)

Cup‐like blasts in acute myeloid leukaemia with NPM1 and IDH2 mutations
por: Ohya, Eiko, et al.
Publicado: (2021)

A Curious Novel Combination of Nucleophosmin (NPM1) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of NPM1 in Acute Myeloid Leukemia (AML)
por: Venanzi, Alessandra, et al.
Publicado: (2021)

EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML
por: Skayneh, Hala, et al.
Publicado: (2022)

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
por: Fiskus, Warren, et al.
Publicado: (2023)

Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML)
por: Djamai, Hanane, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rgd274o7e7jkfvc2vuq61jeltp